Fiscal Period | 2024 |
---|---|
Period End Date | Jun 23 |
Revenue | 11940.84 |
Total Revenue | 11940.84 |
Costof Revenue Total | 2758.17 |
Gross Profit | 9182.67 |
Selling/ General/ Admin Expenses Total | 2402.04 |
Depreciation/ Amortization | 651.32 |
Unusual Expense( Income) | 322.87 |
Other Operating Expenses Total | 3450.90 |
Total Operating Expense | 9585.30 |
Operating Income | 2355.54 |
Interest Inc( Exp) Net- Non- Op Total | -788.40 |
Other Net | 204.44 |
Net Income Before Taxes | 2481.14 |
Provisionfor Income Taxes | 468.10 |
Net Income After Taxes | 2013.04 |
Minority Interest | 16.89 |
Equity In Affiliates | -73.90 |
Net Income Before Extra Items | 2022.54 |
Net Income | 2022.54 |
Income Availableto Com Excl Extra Ord | 2022.54 |
Income Availableto Com Incl Extra Ord | 2022.54 |
Diluted Net Income | 2022.54 |
Diluted Weighted Average Shares | 240.78 |
Diluted EPS Excluding Extra Ord Items | 8.40 |
DPS- Common Stock Primary Issue | 0.00 |
Diluted Normalized EPS | 9.49 |
Sun Pharmaceutical Industries Dividend | Sun Pharmaceutical Industries Bonus | Sun Pharmaceutical Industries News | Sun Pharmaceutical Industries AGM | Sun Pharmaceutical Industries Rights | Sun Pharmaceutical Industries Splits | Sun Pharmaceutical Industries Board Meetings | Sun Pharmaceutical Industries Key Metrics | Sun Pharmaceutical Industries Shareholdings | Sun Pharmaceutical Industries Profit Loss | Sun Pharmaceutical Industries Balance Sheet | Sun Pharmaceutical Industries Cashflow | Sun Pharmaceutical Industries Q2 Results | Sun Pharmaceutical Industries Q3 Results | Sun Pharmaceutical Industries Q4 Results
Top Gainers | Top Losers | Indian Indices | BSE Active Stocks | NSE Active Stocks